Identifying Good Candidates for Active Surveillance of Ductal Carcinoma
Journal
Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
01
08
2022
revised:
12
09
2022
accepted:
16
11
2022
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Ductal carcinoma A retrospective analysis of 71 patients with DCIS who did not undergo upfront surgery demonstrated that breast MRI features after short-term exposure to endocrine therapy identify those at high (68.2%), intermediate (20.0%), and low risk (8.7%) of IDC. With 7.4 years mean follow-up, 52.1% of patients remain on active surveillance. A period of active surveillance offers the opportunity to risk-stratify DCIS lesions and guide decisions for operative management.
Identifiants
pubmed: 36970720
doi: 10.1158/2767-9764.CRC-22-0263
pii: CRC-22-0263
pmc: PMC10035518
doi:
Types de publication
Observational Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Pagination
1579-1589Subventions
Organisme : NCI NIH HHS
ID : U01 CA111234
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA196406
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA251070
Pays : United States
Informations de copyright
© 2022 The Authors; Published by the American Association for Cancer Research.
Déclaration de conflit d'intérêts
R.A. Mukhtar reports other from Exact Sciences during the conduct of the study. G.L. Hirst reports she/her partner holds stock in Moderna, Nanostring, Gilead Sciences, and Exact Sciences which represents <1% of company value. None of these companies are involved in this described study. L.J. Esserman reports personal fees from Blue Cross Medical Advisory Panel; grants from Quantum Leap Healthcare Collaborative and Merck outside the submitted work. No disclosures were reported by the other authors.
Références
J Clin Oncol. 2019 Apr 20;37(12):954-963
pubmed: 30625040
J Natl Cancer Inst. 2011 Mar 16;103(6):478-88
pubmed: 21398619
Eur J Cancer. 2015 Nov;51(16):2296-303
pubmed: 26296293
Lancet Oncol. 2014 May;15(6):e234-42
pubmed: 24807866
J Clin Oncol. 2009 Jan 10;27(2):279-88
pubmed: 19064970
Eur J Cancer. 2015 Aug;51(12):1497-510
pubmed: 26025767
JAMA. 2015 Mar 17;313(11):1122-32
pubmed: 25781441
J Chronic Dis. 1984;37(9-10):721-31
pubmed: 6501544
Cancer. 2005 May 1;103(9):1778-84
pubmed: 15770688
Curr Oncol Rep. 2019 Mar 5;21(4):33
pubmed: 30834994
JAMA Oncol. 2020 Sep 1;6(9):1355-1362
pubmed: 32701140
Transl Oncol. 2020 Apr;13(4):100756
pubmed: 32208353
Nat Rev Cancer. 2010 Feb;10(2):87-101
pubmed: 20094044
JAMA Oncol. 2015 Oct;1(7):881-3
pubmed: 26291410
J Natl Cancer Inst. 2010 May 5;102(9):605-13
pubmed: 20413742
J Clin Oncol. 2014 Nov 10;32(32):3613-8
pubmed: 25311220
J Natl Cancer Inst Monogr. 2010;2010(41):162-77
pubmed: 20956824
Future Oncol. 2019 Jan;15(2):207-224
pubmed: 30156427
JAMA Netw Open. 2020 Sep 1;3(9):e2017124
pubmed: 32936299
J Clin Oncol. 2020 Apr 20;38(12):1284-1292
pubmed: 32125937
Cell. 2018 Jan 11;172(1-2):205-217.e12
pubmed: 29307488
BMJ Open. 2019 Mar 12;9(3):e026797
pubmed: 30862637
JAMA. 2013 Aug 28;310(8):797-8
pubmed: 23896967
N Engl J Med. 2020 Apr 16;382(16):1557-1563
pubmed: 32294352
Lancet Oncol. 2011 Jan;12(1):21-9
pubmed: 21145284
Ann Intern Med. 2016 May 17;164(10):649-55
pubmed: 26999810
Annu Rev Med. 2017 Jan 14;68:197-211
pubmed: 28099081
J Theor Biol. 2005 Jan 21;232(2):179-89
pubmed: 15530488
Breast Cancer Res Treat. 2014 Jan;143(2):343-50
pubmed: 24346130
J Clin Oncol. 2019 Jul 1;37(19):1629-1637
pubmed: 30973790
BMC Cancer. 2015 Nov 10;15:890
pubmed: 26555555
J Clin Oncol. 2013 Nov 10;31(32):4054-9
pubmed: 24043739